Article Sidebar

PDF
Date Published: 08/06/2021
Abstract Views: 503
Views PDF: 248
DOI: https://doi.org/10.51298/vmj.v500i1.340
Issue
Vol. 500 No. 1 (2021)
Section
Các bài báo
How to Cite
Ngọc Rạng, N., & Thanh Minh Châu, T. . (2021). THE EFFECTIVENESS OF IRON-CHELATION THERAPY IN CHILDREN WITH BETA-THALASSEMIA MAJOR AT THE WOMEN AND CHILDREN HOSPITAL OF AN GIANG. Vietnam Medical Journal, 500(1). https://doi.org/10.51298/vmj.v500i1.340

THE EFFECTIVENESS OF IRON-CHELATION THERAPY IN CHILDREN WITH BETA-THALASSEMIA MAJOR AT THE WOMEN AND CHILDREN HOSPITAL OF AN GIANG

Nguyễn Ngọc Rạng, Trang Thanh Minh Châu

Main Article Content

Abstract

Objectives: The purpose of this study was to evaluate the effectiveness of iron-chelation therapy with deferoxamine (DFO) versus deferiprone (DFP) in patients with beta-thalassemia. Patients and methods: Our cohort study was performed in 44 patients with beta-thalassemia major (17 patients received DFO, 27 patients received DFP). DFO was administered subcutaneously in a total daily dose of 25-35 mg/kg for 3-4 days per week and DFP was administered orally in a total daily dose of 75 mg/kg for 6 days per week. The efficacy of treatment was assessed by measurements of serum ferritin and transaminase (AST, ALT) levels. Results: Out of the 44 patients, 17 receiving DFO showed a good results. After 12-month therapy, their median serum ferritin levels reduced from 4362 to 3022 ng/mL (p= 0.024) and their median AST/ALT reduced from 88/77 U/L to 54/56 U/L ( p< 0,001). Whereas, 27 patients receiving oral DFP showed no effectiveness for reducing serum ferritin level, increased from 4417 to 4882 ng/mL (p= 0.825) and the transaminases (AST/ALT) did not decrease after 12 month iron-chelation therapy (p> 0.05). Conclusions: The results of this study show that iron-chelation therapy with DFO results in satisfactory reduction of serum ferritin and liver transaminases, whereas oral DPF is ineffective in iron chelation in patients with beta-thalassemia major

Article Details

Keywords

Thalassemia major, iron chelation, deferoxamin, defeprirone

References

1. Svasti ML, Hieu TM, Munkongdee T, et al. (2002) Molecular analysis of beta-thalassemia in South Vietnam. Am J Hematol. 71(2):85-88.
2. Lâm Thị Mỹ (2009) Website BV Nhi Đồng I: http://www.nhidong.org.vn/ Default.aspx
3. Rund D. and Rachmilewitz E. (2000) New trends in the treatment of b-thalassemia. Critical Rewiews in Oncology:Hematology 33:105– 118
4. Olivieri NF, Brittenham GM. (1997) Iron-chelating therapy and the treatment of thalassemia. Blood. 1;89(3):739-61.
5. Modell B, Khan M, Darlison M. (2000) Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 10;355(9220):2051-2.
6. Jamuar SS, Lai AH. (2012) Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia. Ther Adv Hematol. 3(5):299-307.
7. Botzenhardt S, Felisi M, Bonifazi D, et al. (2018) Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study. Haematologica. 103(1):e1-e4.
8. Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. (2003) Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 121(1):187-9.
9. Waheed N, Ali S, Butt MA. (2014) Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major. J Ayub Med Coll Abbottabad. 26(3):297-300.